Demographics, risk factors, clinical history, treatments and outcomes in non-tirofiban group
| Patients | Sex/age (y) | Risk factors | Evidence of AP by CTA | NE before treatment | Duration of the episodes | Maximum NIHSS | Treatments | Fluctuation after treatments | NIHSSs at 24 hours | 3 months mRS | Site of IL on MRI |
| 1 | F/66 | Hy, DM | + | 3 | 20 m | 15 | rt-PA, LMWHs, hydration | + | 12 | 1 | LSA-L |
| 2 | M/31 | Hy, Dy, CS, CD | − | 3 | 5–60 m | 13 | rt-PA, aspirin (100 mg), clopidogrel (300 mg), LMWHs, hydration | + | 1 | 0 | AChA-L |
| 3 | M/55 | Hy, Dy | + | 4 | 5–10 m | 11 | Aspirin (100 mg), clopidogrel (300 mg), LMWHs, vasopressors | − | 0 | 0 | / |
| 4 | M/76 | Hy, DM | + | 3 | 5–180 m | 7 | Aspirin (100 mg), LMWHs, hydration | + | 7 | 1 | PP-R |
| 5 | M/47 | Hy, Dy, CS, CD | − | 4 | 30 m | 9 | Aspirin (100 mg), LMWHs, | + | 8 | 1 | AChA-L |
| 6 | F/55 | Dy | + | 3 | 1–10 m | 2 | Clopidogrel (300 mg), LMWHs, hydration | − | 1 | 0 | DWI (-) |
| 7 | M/59 | Dy, CS, CD | − | 4 | 60 m | 10 | Aspirin (100 mg), clopidogrel (300 mg), hydration | + | 10 | 4 | AChA-L |
| 8 | M/57 | Dy | + | >4 | 4–6 m | 3 | Aspirin (100 mg), clopidogrel (300 mg), hydration | − | 0 | 0 | DWI (-) |
AChA-L, territory of left anterior choroidal artery; AP, atheromatous plaque; CD, current drinking; CS, current smoker; CTA, CT angiography; DM, diabetes mellitus; Dy, dyslipidaemia; DWI, diffusion-weighted imaging; Hy, hypertension; IL, infarct location; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NE, number of episodes; PP-R, right paramedian pontine; /, not available; y, years of age.